Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.

Bartels F, Nobis K, Cooper G, Wendel E, Cleaveland R, Bajer-Kornek B, Blaschek A, Schimmel M, Blankenburg M, Baumann M, Karenfort M, Finke C, Rostásy K.

Mult Scler. 2019 Jun;25(7):927-936. doi: 10.1177/1352458519829698. Epub 2019 Apr 4.

PMID:
30945587
2.

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.

Walter E, Berger T, Bajer-Kornek B, Deisenhammer F.

J Med Econ. 2019 Mar;22(3):226-237. doi: 10.1080/13696998.2018.1556668. Epub 2018 Dec 21.

PMID:
30522373
3.

Paediatric multiple sclerosis and other acute demyelinating diseases.

Rostásy K, Bajer-Kornek B.

Curr Opin Neurol. 2018 Jun;31(3):244-248. doi: 10.1097/WCO.0000000000000562. Review.

PMID:
29629942
4.

Epidemiology of Multiple Sclerosis in Austria.

Salhofer-Polanyi S, Cetin H, Leutmezer F, Baumgartner A, Blechinger S, Dal-Bianco A, Altmann P, Bajer-Kornek B, Rommer P, Guger M, Leitner-Bohn D, Reichardt B, Alasti F, Temsch W, Stamm T.

Neuroepidemiology. 2017;49(1-2):40-44. doi: 10.1159/000479696. Epub 2017 Aug 19.

PMID:
28848208
5.

Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.

Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, Brantner-Inthaler S, Diepold K, Eisenkölbl A, Gotwald T, Kuchukhidze G, Gruber-Sedlmayr U, Häusler M, Höftberger R, Karenfort M, Klein A, Koch J, Kraus V, Lechner C, Leiz S, Leypoldt F, Mader S, Marquard K, Poggenburg I, Pohl D, Pritsch M, Raucherzauner M, Schimmel M, Thiels C, Tibussek D, Vieker S, Zeches C, Berger T, Reindl M, Rostásy K; BIOMARKER Study Group.

Neurology. 2017 Aug 29;89(9):900-908. doi: 10.1212/WNL.0000000000004312. Epub 2017 Aug 2.

6.

Similar impact of multiple sclerosis and migraine on sexual function in women : Is the multiple sclerosis impact scale questionnaire useful?

Salhofer-Polanyi S, Wöber C, Prohazka R, Dal-Bianco A, Bajer-Kornek B, Zebenholzer K.

Wien Klin Wochenschr. 2017 Feb;129(3-4):115-120. doi: 10.1007/s00508-016-1066-x. Epub 2016 Sep 5.

7.

Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders.

Rostasy K, Bajer-Kornek B, Venkateswaran S, Hemingway C, Tardieu M.

Neurology. 2016 Aug 30;87(9 Suppl 2):S28-37. doi: 10.1212/WNL.0000000000002878. Review.

PMID:
27572858
8.

Pediatric multiple sclerosis: Escalation and emerging treatments.

Chitnis T, Ghezzi A, Bajer-Kornek B, Boyko A, Giovannoni G, Pohl D.

Neurology. 2016 Aug 30;87(9 Suppl 2):S103-9. doi: 10.1212/WNL.0000000000002884. Review.

PMID:
27572854
9.

Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients.

Schmied MC, Zehetmayer S, Reindl M, Ehling R, Bajer-Kornek B, Leutmezer F, Zebenholzer K, Hotzy C, Lichtner P, Meitinger T, Wichmann HE, Illig T, Gieger C, Huber K, Khalil M, Fuchs S, Schmidt H, Auff E, Kristoferitsch W, Fazekas F, Berger T, Vass K, Zimprich A.

Neurogenetics. 2012 May;13(2):181-7. doi: 10.1007/s10048-012-0316-y. Epub 2012 Mar 14.

PMID:
22411505
10.

Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis.

Rostasy K, Mader S, Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M, Tibussek D, Blaschek A, Bajer-Kornek B, Leitz S, Schimmel M, Di Pauli F, Berger T, Reindl M.

Arch Neurol. 2012 Jun;69(6):752-6. doi: 10.1001/archneurol.2011.2956.

PMID:
22371853
11.

Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.

Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, Deisenhammer F, Reindl M, Berger T.

Clin Immunol. 2011 Mar;138(3):247-54. doi: 10.1016/j.clim.2010.11.013. Epub 2010 Dec 18.

PMID:
21169067

Supplemental Content

Loading ...
Support Center